Plus Therapeutics Inc (PSTV)

02:24 AM

What is HC Wainwright’s Estimate for PSTV FY2029 Earnings? - Defense World

02:24 AM

Mar 30, 2025

Plus Therapeutics (NASDAQ:PSTV) Earns “Buy” Rating from D. Boral Capital - Defense World

Mar 30, 2025

Mar 29, 2025

Plus Therapeutics outlines REYOBIQ expansion plans and CNSide launch timeline - MSN

Mar 29, 2025

Mar 29, 2025

Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer - AOL

Mar 29, 2025

Mar 28, 2025

Earnings call transcript: Plus Therapeutics’ Q4 2024 results highlight innovation - Investing.com Australia

Mar 28, 2025

Mar 28, 2025

H.C. Wainwright cuts Plus Therapeutics price target to $5.50 By Investing.com - Investing.com Australia

Mar 28, 2025

Mar 28, 2025

H.C. Wainwright cuts Plus Therapeutics price target to $5.50 - Investing.com India

Mar 28, 2025

Mar 28, 2025

Promising Outlook for Plus Therapeutics: Strategic Financial Moves and Innovative Assay Launch Justify Buy Rating - TipRanks

Mar 28, 2025

Mar 28, 2025

Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance

Mar 28, 2025

Mar 28, 2025

Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: S - GuruFocus

Mar 28, 2025

Mar 28, 2025

Plus Therapeutics Reports 2024 Financial Results and Progress - TipRanks

Mar 28, 2025

Mar 27, 2025

Plus Therapeutics (PSTV) Reports Mixed FY Results, Revenue Surges - GuruFocus

Mar 27, 2025

Mar 27, 2025

Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Mar 27, 2025

Mar 27, 2025

Plus Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025

Mar 27, 2025

PLUS THERAPEUTICS Earnings Results: $PSTV Reports Quarterly Earnings - Nasdaq

Mar 27, 2025

Mar 27, 2025

Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire

Mar 27, 2025

Mar 27, 2025

Plus Therapeutics Doubles Survival Rates in Brain Cancer Trial, Raises $15M to Accelerate Growth - Stock Titan

Mar 27, 2025

Mar 26, 2025

A Peek at Plus Therapeutics's Future Earnings - Benzinga

Mar 26, 2025

Mar 25, 2025

PLUS THERAPEUTICS Earnings Preview: Recent $PSTV Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 25, 2025

Mar 25, 2025

Plus Therapeutics Introduces REYOBIQ - citybiz

Mar 25, 2025

Mar 21, 2025

PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug - TradingView

Mar 21, 2025

Mar 21, 2025

Thursday's Trending Pharma Stock Plus Therapeutics, Inc. (Nasdaq: PSTV) Gains 170% - Investorideas.com

Mar 21, 2025

Mar 21, 2025

Why Plus Therapeutics Inc. (PSTV) Surged On Thursday? - Insider Monkey

Mar 21, 2025

Mar 20, 2025

10 Micro-, Small-Cap Firms Dominate Thursday’s Gains - Insider Monkey

Mar 20, 2025

Mar 20, 2025

Plus Therapeutics Shares Jump After FDA Accepts Name of Lead Tumor Treatment Candidate - Marketscreener.com

Mar 20, 2025

Mar 20, 2025

FDA conditionally accepts new name for Plus Therapeutics drug By Investing.com - Investing.com South Africa

Mar 20, 2025

Mar 20, 2025

Plus Therapeutics announces FDA conditionally accepted name REYOBIQ - TipRanks

Mar 20, 2025

Mar 20, 2025

FDA conditionally accepts new name for Plus Therapeutics drug - Investing.com India

Mar 20, 2025

Mar 20, 2025

Why Plus Therapeutics Is Rising In Pre-market? - Nasdaq

Mar 20, 2025

Mar 20, 2025

Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate - GlobeNewswire

Mar 20, 2025

Mar 20, 2025

Plus Therapeutics Scores FDA Recognition for REYOBIQ Cancer DrugMajor Milestone for CNS Treatment - StockTitan

Mar 20, 2025

Mar 19, 2025

Plus Therapeutics Sets Earnings Date: CNS Cancer Drug Developer to Report Q4 Results - StockTitan

Mar 19, 2025

Mar 19, 2025

Plus Therapeutics, Inc. to Announce Q4 and Full Year 2024 Financial Results on March 27, 2025 - Nasdaq

Mar 19, 2025

Mar 19, 2025

Plus Therapeutics to Announce Fourth Quarter and Full Year - GlobeNewswire

Mar 19, 2025

Mar 18, 2025

Plus Therapeutics (NASDAQ:PSTV) Now Covered by Analysts at D. Boral Capital - Defense World

Mar 18, 2025

Mar 17, 2025

Plus Therapeutics stock gains on Boral Capital Buy rating By Investing.com - Investing.com South Africa

Mar 17, 2025

Mar 17, 2025

Plus Therapeutics stock gains on Boral Capital Buy rating - Investing.com India

Mar 17, 2025

Mar 17, 2025

D. Boral Capital Initiates Coverage of Plus Therapeutics (PSTV) with Buy Recommendation - Nasdaq

Mar 17, 2025

Mar 17, 2025

Plus Therapeutics initiated with a Buy at D. Boral Capital - TipRanks

Mar 17, 2025

Mar 16, 2025

Plus Therapeutics regains compliance with Nasdaq minimum stockholders’ equity requirement - MSN

Mar 16, 2025

Mar 11, 2025

D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement - Bluefield Daily Telegraph

Mar 11, 2025

Mar 11, 2025

Plus Therapeutics Raises $15M: Strategic Financial Move Includes Debt Conversion - StockTitan

Mar 11, 2025

Mar 10, 2025

Plus Therapeutics Regains Nasdaq Compliance - Nasdaq

Mar 10, 2025

Mar 10, 2025

Plus Therapeutics regains Nasdaq compliance status By Investing.com - Investing.com Australia

Mar 10, 2025

Mar 10, 2025

Plus Therapeutics regains Nasdaq compliance - Investing.com India

Mar 10, 2025

Mar 10, 2025

SEC Form 424B3 filed by PLUS THERAPEUTICS Inc. - Quantisnow

Mar 10, 2025

Mar 10, 2025

Plus Therapeutics regains Nasdaq compliance status - Investing.com India

Mar 10, 2025

Mar 10, 2025

Plus Therapeutics Regains Compliance With Nasdaq Minimum Stockholders' Equity Requirement - Marketscreener.com

Mar 10, 2025